None

Lonza to develop OncoMed anti-cancer therapeutics

Lonza has signed an agreement with OncoMed to develop and manufacture OncoMed's pipeline of anti-cancer stem cell therapeutics.

OncoMed contracts Lonza to manufacture cancer drugs

Lonza will develop and manufacture OncoMed's pipeline of experimental stem cell treatments for cancer.  -More- 

OncoMed Pharmaceuticals initiates PI Trial of Anti-Cancer Stem Cell Therapeutic

   Cell Therapeutic OMP-54F28 (Fzd8-Fc)   OncoMed Pharmaceuticals, a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells has beg...

FDA Clears OncoMed's Demcizumab (Anti-DLL4) to Resume Clinical Testing in the US

Partial Clinical Hold Removed By FDA REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 2, 2013 - OncoMed Pharmaceuticals, a clinical-stage company developing novel therapeutics that target cancer stem cells...

MorphoSys-Aktie: OncoMed beginnt klinische Phase-1b/2-Studie mit HuCAL-Antikörper OMP-59R5 im Bereich Pankreaskrebs

Martinsried - Der Biotechnologiekonzern MorphoSys AG (ISIN DE0006632003/ WKN 663200) gab am Freitag bekannt, dass sein Kooperationspartner OncoMed Pharmaceuticals den HuCAL-Antikörper OMP-59R5 in d.....

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progre...

OncoMed commences OMP-59R5 Phase 1b/2 small cell lung cancer trial

OncoMed Pharmaceuticals has commenced Phase 1b/2 trial of anti-cancer stem cell therapeutic OMP-59R5 (Anti-Notch2/3) in small cell lung cancer (SCLC) patients.

MorphoSys AG: MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase 1b/2 Clinical Trial in Pancreatic Cancer

MorphoSys AG / MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase 1b/2 Clinical Trial in Pancreatic Cancer . Processed and transmitted by Thomson Reuters ONE. The issuer is...

None